Participate in Research at CU Anschutz

The purpose of this study is to learn more about the effects of the study drug larotrectinib and how well it works to shrink brain tumors when used alone or when given with standard chemotherapy or after radiation therapy. Patients in this research study have been diagnosed with a high-grade glioma with a certain abnormal gene called NTRK.

All participants will receive the study drug, larotrectinib. Patients may continue to take the study drug for up to 20 months if there aren't any side effects and their brain tumor does not get worse. Patients will be given a diary to write down the amount of study drugs (number of pills or amount of liquid) taken each day, the time taken and any missed doses. Treatment paths: After completing the first 2 cycles of larotrectinib, the next treatment received will depend on the response as seen on the MRI imaging and any changes seen in tumor size. If the tumor went away patients will continue to receive larotrectinib alone. If the tumor stayed the same or became smaller (shrink) patients will be able to remain on the research study and receive larotrectinib along with standard treatment for your brain tumor. Standard treatment may include chemotherapy or radiation therapy. If the tumor grew in size, patients will be removed from study treatment.